Compare HBIO & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBIO | KTTA |
|---|---|---|
| Founded | 1901 | 2020 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5M | 18.1M |
| IPO Year | 2000 | N/A |
| Metric | HBIO | KTTA |
|---|---|---|
| Price | $6.10 | $0.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $18.00 | $3.00 |
| AVG Volume (30 Days) | 20.6K | ★ 436.1K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $116,176,000.00 | N/A |
| Revenue This Year | $4.77 | N/A |
| Revenue Next Year | $8.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $0.28 |
| 52 Week High | $7.50 | $2.06 |
| Indicator | HBIO | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 49.83 | 35.96 |
| Support Level | $5.91 | $0.49 |
| Resistance Level | $6.79 | $0.76 |
| Average True Range (ATR) | 0.34 | 0.05 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 25.40 | 37.62 |
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.